<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02592200</url>
  </required_header>
  <id_info>
    <org_study_id>CSUB0092</org_study_id>
    <nct_id>NCT02592200</nct_id>
  </id_info>
  <brief_title>Effect of Lactobacillus Gasseri DSM 27123 on Functional Constipation in Healthy Women</brief_title>
  <official_title>A Double Blind Placebo-Controlled Study on the Effect of the Probiotic Lactobacillus Gasseri DSM 27123 on Functional Constipation in Healthy Women - Proof of Concept</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioGaia AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioGaia AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to determine the change in frequency of complete spontaneous bowel&#xD;
      movements (CSBMs) after 4 weeks of oral supplementation with Lactobacillus gasseri DSM 27123&#xD;
      in healthy adult women with functional constipation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects to complete study diaries, number of SBM, CSBM, form of faeces (according to the&#xD;
      Bristol Stool Form scale), pain during defecation (according to the visual analogue scale&#xD;
      [VAS] 0-100), time spent at each evacuation, episodes of faecal incontinence, number of&#xD;
      ingested capsules of investigational product will be recorded daily by the subjects&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 5, 2015</start_date>
  <completion_date type="Actual">July 31, 2016</completion_date>
  <primary_completion_date type="Actual">June 21, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in frequency of complete spontaneous bowel movements (CSBMs)</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Stool Consistency (Bristol Stool Form scale)</measure>
    <time_frame>Baseline, week 1, 2, 3 and 4</time_frame>
    <description>Change in Bristol Stool Form Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient-Assessment of Constipation Symptoms (PAC-SYM)</measure>
    <time_frame>Baseline, week 1, 2, 3 and 4 (change from baseline)</time_frame>
    <description>Change in score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Gastrointestinal Symptom Rating Scale (GSRS)</measure>
    <time_frame>Baseline, week 1, 2, 3 and 4</time_frame>
    <description>Change in Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of responders</measure>
    <time_frame>4 weeks</time_frame>
    <description>Proportion of responders is defined as subjects showing a mean increase of ≥1 CSBM per week during the treatment period (Day 1 to Day 28) compared to the baseline period (Day-14 to Day -1) or ≥3 CSBMs in the last week of the treatment period (Day 21 to Day 28). The subjects will record time and date of all CSBMs in the study diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatement related adverse events</measure>
    <time_frame>During the whole study - 4 weeks</time_frame>
    <description>Descriptive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Lactobacillus gasseri DSM 27123 in faeces</measure>
    <time_frame>4 weeks</time_frame>
    <description>qPCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for laxative medication</measure>
    <time_frame>During the treatment period - 4 weeks</time_frame>
    <description>Time and date of laxative use will be recorded in the study diary by the subjects.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Functional Constipation</condition>
  <arm_group>
    <arm_group_label>Lactobacillus gasseri</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lactobacillus gasseri DSM 27123 capsules, 1×109 CFU (divided in two doses)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules (two doses)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus gasseri DSM 27123</intervention_name>
    <description>109 CFU (divided in two doses) per day for 28 days</description>
    <arm_group_label>Lactobacillus gasseri</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Two doses per day for 28 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        The subjects have to meet all of the following criteria to be eligible to enter the study:&#xD;
&#xD;
          1. Willing and able to provide informed consent&#xD;
&#xD;
          2. Women aged 18-49 years at Visit 1&#xD;
&#xD;
          3. BMI ≥18 and ≤29 at Visit 1&#xD;
&#xD;
          4. Suffering of functional constipation as defined by the Rome III criteria for&#xD;
             functional constipation&#xD;
&#xD;
          5. Comply with the requirement not to use any other probiotic products from Visit 1 and&#xD;
             throughout the study period&#xD;
&#xD;
          6. Not pregnant or breastfeeding&#xD;
&#xD;
          7. Using adequate contraceptive measures&#xD;
&#xD;
          8. Ability to understand and comply with the requirements of the study, as judged by the&#xD;
             Investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hypersensitivity or allergy to the investigational product, to chemically related&#xD;
             products or to comparator/placebo&#xD;
&#xD;
          2. Well-known, organic cause of constipation&#xD;
&#xD;
          3. Anorectal pathology&#xD;
&#xD;
          4. Previous gastrointestinal surgery&#xD;
&#xD;
          5. Any alarming symptoms (i.e. rectal bleeding, weight loss, jaundice) as judged by the&#xD;
             Investigator&#xD;
&#xD;
          6. Spinal anomalies and injuries&#xD;
&#xD;
          7. Use of antibiotics within 4 weeks prior to Visit 1&#xD;
&#xD;
          8. Use of products containing probiotics more than once a week in the previous 3 weeks&#xD;
&#xD;
          9. Mental or behavioural disorders as judged by the Investigator&#xD;
&#xD;
         10. Food allergy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per Hellström, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uppsala University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CTC, Akademiska Sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 22, 2015</study_first_submitted>
  <study_first_submitted_qc>October 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2015</study_first_posted>
  <last_update_submitted>December 30, 2020</last_update_submitted>
  <last_update_submitted_qc>December 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Female</keyword>
  <keyword>Constipation</keyword>
  <keyword>Lactobacillus gasseri DSM 27123</keyword>
  <keyword>Probiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

